Expression of the estrogen receptor during differentiation of human osteoclasts

Steroids

Volumn 73, Issue 7, 2008, Pages 765-774

  Denger, Stefanie ^a   Reid, George ^a   Gannon, Frank ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Estrogen receptor isoforms; Osteoclast differentiation

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; PROTEIN PS2;

ADULT; ARTICLE; BONE TURNOVER; CELL CULTURE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEVELOPMENTAL GENE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PS2 GENE; SIGNAL TRANSDUCTION;

BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION PROFILING; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MONOCYTES; OSTEOCLASTS; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 43649108053     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.02.013     Document Type: Article

References (56)

1. Manolagas S.C., Kousteni S., and Jilka R.L. Sex steroids and bone. Recent Prog Horm Res 57 (2002) 385-409
2. Compston J.E. Sex steroids and bone. Physiol Rev 81 1 (2001) 419-447
3. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 9322 (2002) 2018-2026
4. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 9321 (2002) 1929-1936
5. Melton L.J., Achenbach S.J., O'fallon W.M., and Khosla S. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone 31 1 (2002) 119-125
6. Takeshita S., Namba N., Zhao J.J., Jiang Y., Genant H.K., Silva M.J., et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8 9 (2002) 943-949
7. Roodman G.D. Cell biology of the osteoclast. Exp Hematol 27 8 (1999) 1229-1241
8. Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanley E.R., et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91 1 (1993) 257-263
9. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 6717 (1999) 315-323
10. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 2 (1998) 165-176
11. Kitazawa R., Kitazawa S., and Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta 1445 1 (1999) 134-141
12. Martin T.J., Quinn J.M., Gillespie M.T., Ng K.W., Karsdal M.A., and Sims N.A. Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 1068 (2006) 458-470
13. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 18 (2007) 1809-1822
14. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 92 3 (2007) 747-753
15. Parikka V., Lehenkari P., Sassi M.L., Halleen J., Risteli J., Harkonen P., et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 142 12 (2001) 5371-5378
16. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., and Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276 12 (2001) 8836-8840
17. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., and Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2 10 (1996) 1132-1136
18. Gorski J., and Gannon F. Current models of steroid hormone action: a critique. Annu Rev Physiol 38 (1976) 425-450
19. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 6058 (1986) 134-139
20. Horwitz K.B., Jackson T.A., Bain D.L., Richer J.K., Takimoto G.S., and Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 10 10 (1996) 1167-1177
21. Graham J.D., Bain D.L., Richer J.K., Jackson T.A., Tung L., and Horwitz K.B. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids 65 10-11 (2000) 579-584
22. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11 3 (2003) 695-707
23. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 6 (2003) 751-763
24. Gaub M.P., Bellard M., Scheuer I., Chambon P., and Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63 6 (1990) 1267-1276
25. Stein B., and Yang M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15 9 (1995) 4971-4979
26. Denger S., Reid G., Kos M., Flouriot G., Parsch D., Brand H., et al. ERalpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 15 12 (2001) 2064-2077
27. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J 19 17 (2000) 4688-4700
28. Li L., Haynes M.P., and Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100 8 (2003) 4807-4812
29. Merot Y., Metivier R., Penot G., Manu D., Saligaut C., Gannon F., et al. The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha (ER alpha) transcriptional activity depends upon the differentiation stage of the cell. J Biol Chem (2004)
30. Tsurukai T., Udagawa N., Matsuzaki K., Takahashi N., and Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab 18 4 (2000) 177-184
31. Patlak M. Bone builders: the discoveries behind preventing and treating osteoporosis. FASEB J 15 10 (2001) 1677E
32. Marcus R., Wong M., Heath III H., and Stock J.L. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23 1 (2002) 16-37
33. Flouriot G., Griffin C., Kenealy M., Sonntag-Buck V., and Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol Endocrinol 12 12 (1998) 1939-1954
34. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., and Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2 (1996) 1132-1136
35. Fuller K., Lean J.M., Bayley K.E., Wani M.R., and Chambers T.J. A role for TGFbeta (1) in osteoclast differentiation and survival. J Cell Sci 113 Pt 13 (2000) 2445-2453
36. Ozmen B., Kirmaz C., Aydin K., Kafesciler S.O., Guclu F., and Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-a, TGFb and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 18 3 (2007) 31-36
37. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., and Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10 24 (1982) 7895-7903
38. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 6 (2000) 843-852
39. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115 12 (2005) 3318-3325
40. Sato M., Grese T.A., Dodge J.A., Bryant H.U., and Turner C.H. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem 42 1 (1999) 1-24
41. Chan G.K., and Duque G. Age-related bone loss: old bone, new facts. Gerontology 48 2 (2002) 62-71
42. Kanatani M., Sugimoto T., Takahashi Y., Kaji H., Kitazawa R., and Chihara K. Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J Bone Miner Res 13 5 (1998) 854-862
43. Ramalho A.C., Couttet P., Baudoin C., Morieux C., Graulet A.M., de Vernejoul M.C., et al. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur Cytokine Netw 13 1 (2002) 39-45
44. Brubaker K.D., and Gay C.V. Specific binding of estrogen to osteoclast surfaces. Biochem Biophys Res Commun 200 2 (1994) 899-907
45. Mano H., Yuasa T., Kameda T., Miyazawa K., Nakamaru Y., Shiokawa M., et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun 223 3 (1996) 637-642
46. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., and Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91 12 (1994) 5227-5231
47. Fiorelli G., Gori F., Petilli M., Tanini A., Benvenuti S., Serio M., et al. Functional estrogen receptors in a human preosteoclastic cell line. Proc Natl Acad Sci USA 92 7 (1995) 2672-2676
48. Hoyland J.A., Mee A.P., Baird P., Braidman I.P., Mawer E.B., and Freemont A.J. Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone 20 2 (1997) 87-92
49. Ohashi T., Kusuhara S., and Ishida K. Immunoelectron microscopic demonstration of estrogen receptors in osteogenic cells of Japanese quail. Histochemistry 96 1 (1991) 41-44
50. Collier F.M., Huang W.H., Holloway W.R., Hodge J.M., Gillespie M.T., Daniels L.L., et al. Osteoclasts from human giant cell tumors of bone lack estrogen receptors. Endocrinology 139 3 (1998) 1258-1267
51. Cummings S.R., Duong T., Kenyon E., Cauley J.A., Whitehead M., and Krueger K.A. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287 (2002) 216-220
52. Langer R.D. Hormone replacement and the prevention of cardiovascular disease. Am J Cardiol 89 12 Suppl (2002) 36E-46E
53. Rosano G.M., Vitale C., and Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?. Ann N Y Acad Sci 1092 (2006) 341-348
54. Sorensen M.G., Henriksen K., Dziegiel M.H., Tanko L.B., and Karsdal M.A. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 25 8 (2006) 475-483
55. Kos M., Denger S., Reid G., and Gannon F. Upstream open reading frames regulate the translation of the multiple mRNA variants of the estrogen receptor alpha. J Biol Chem 277 40 (2002) 37131-37138
56. Dauvois S., White R., and Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106 Pt 4 (1993) 1377-1388